Biomarkers are often used to help determine the best treatment for a patient, but not all communities are benefitting from the latest advancements in biomarker testing and precision medicine.
Progress in improving cancer outcomes increasingly involves the use of precision medicine. Biomarker testing is an important step for accessing precision medicine including targeted therapies that can lead to improved survivorship and better quality of life for cancer patients. But without action to expand coverage of and access to biomarker testing, advances in precision medicine could increase existing disparities in cancer outcomes by race, ethnicity, income, and geography.
Biomarker testing coverage for all state-regulated plans: AZ, CA, CT, GA, IL, IN, IA, KY, MD, MN, MS, NE^, NM, NJ, NY, OK, PA, RI, TX
Biomarker testing coverage for some plans: AR*, CO*, FL**, LA*
Legislation introduced in 2026: DE, HI, MA, ME, NH, NC, OH, TN, VT, WA
*Arkansas, Colorado and Louisiana laws apply to state-regulated private plans **Florida law applies to Medicaid and state employee health plan. ^Nebraska law applies to a limited list of diseases and conditions
Effective dates vary.
Last updated March 2026.
It allows doctors to precisely target a specific cancer so patients may not have to undergo more generalized treatments like chemo and radiation that may not work as well for them.
Patient and Provider Stories
|
|
|
|
|
|
